Suffolk pub The George reopens in Wickham Market after 2013 fire
A community has celebrated the return of its only village pub, 12 years after it burned down.Residents of Wickham Market, in Suffolk, saw The George go up in flames in April 2013.A group got together in 2016 to buy the site and a project – boosted by a £1m grant from the National Lottery – came to fruition when the doors reopened on Saturday 9 June."It's run to the benefit of the community and now we're open it's proving to be quite a success," said Colin Owens, project lead of the venue's management committee.
"The volunteer group raised in excess of £2m to complete the project and restore The George to be much more than it was - to be more than a pub."The pub is Grade II listed and dates back to the 16th Century.Plans from a private developer to demolish and redevelop the site were rejected by East Suffolk Council in 2016 due to it being "a building of significant historic interest". Now 476 shareholders own a stake in its future.
An extension to the back of the building includes new kitchen and toilet facilities, with a remodelled layout. An upstairs function room can host 60 people.Its original fireplace was retained and food will start being served later this month, although with table reservations only being taken on Sundays to try maintaining a welcoming atmosphere.Pub manager Ed Leigh said: "It's fantastic. It's been a really pleasurable experience. The whole community has got behind it."The wide range of people – families, older people, younger people – everyone seems to be really relishing the fact that they can take a quick stroll and have a drink or a coffee."Once the food comes on board, we'll be absolutely nailing it."
The new lease of life is welcome news for Brian Hall, one of the shareholders."It's brilliant, we've been waiting for this for a long, long while," said Mr Hall."The first week we had just over 200 people here and that was on limited access until we got fully staffed."
However, the management committee has had some early complaints about noise from neighbours.Mr Leigh added: "There are people in the community, as you would expect in any vibrant community, who are completely opposed to us being here."I am sorry about that."We will do what we can to make things as unobtrusive as possible but we can't do everything."Mr Owens added that a thorough consultation process was carried out in recent years.He said: "In every situation like this, there is bound to be people that object. They tend to be local to the pub and don't particularly want to live near a pub – even though it's been here for 500 years."
Follow Suffolk news on BBC Sounds, Facebook, Instagram and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
26 minutes ago
- Daily Mail
Wood Group takeover talks extended again amid regulatory probe
John Wood Group has again extended the deadline for suitor Sidara to make a concrete takeover offer for the company. It follows the launch of a City watchdog investigation into Wood Group last week after an independent review unearthed 'cultural failings' with its accounting practices. The North Sea-focused oilfield services provider told investors on Monday Dubai-based Sidara now has until 5pm on 28 July to put forward a 'put up or shut up' proposal, having originally given the firm until today to do so. Sidara began a fresh move for Wood Group in February after a previous attempt to acquire the company in a £1.7billion deal last year failed. However, Wood Group refused to accept the offer after two months of talks, blaming 'rising geopolitical risks and financial market uncertainty'. Sidara eventually put forward a far lower 35p per share bid in April, which values Wood Group at around £240million. The offer additionally includes a potential $450million capital injection and Wood Group possibly pursuing an extension or amendment to its current debt facilities. Wood Group shares have plummeted by approximately 84 per cent over the past year amidst cash flow problems, massive contract write-offs and accounting failures. In February, the Edinburgh-based firm warned that it expected between $150million and $200million in negative free cash flow this year owing to subdued trading and legacy claims liabilities totalling about $150million. Its chief financial officer, Arvind Balan, resigned soon afterwards when he admitted to inaccurately describing his professional qualifications. A month later, Wood Group admitted that its previous financial statement would have to be restated after a Deloitte probe uncovered 'material weaknesses and failures' in the financial culture of its projects business. Following delays in publishing its 2024 results, the company's shares were suspended from trading on the London Stock Exchange in April. And just last week, the Financial Conduct Authority (FCA) began its own investigation into Wood Group, which will look at the firm's conduct between January 2023 and November 2024. Founded as Dar al-Handasah in Lebanon in 1956, Sidara is a network of engineering and design companies employing about 21,500 people with a specialist focus on large-scale building projects. Wood Group employs 35,000 individuals across more than 60 countries who give consultation, engineering, and management services to the energy and minerals sectors. Private equity giant Apollo Global Management tried to purchase Wood Group in 2023, making four proposals, including a final offer of 240p per share, before the latter walked away without explanation.
Reuters
33 minutes ago
- Reuters
UK lenders approve more mortgages than expected in May
LONDON, June 30 (Reuters) - British lenders approved 63,032 mortgages in May, more than expected by economists, Bank of England data showed on Monday, suggesting the housing market recovered quickly from the end of a tax break for homebuyers in April. A Reuters poll of economists had pointed to 59,750 mortgage approvals during the month.
Daily Mail
34 minutes ago
- Daily Mail
UK pharma group Hikma ploughs $1bn into US manufacturing as tariff threat lingers
Medicines firm Hikma Pharmaceuticals plans to invest $1billion into US manufacturing and research and development over the next five years. The London-headquartered firm told investors on Monday the investment would expand its domestic capabilities 'to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide'. Hikma specialises in generic medicines - medications created to be the same as a brand-name drug, but usually sold at a lower cost. It comes as the UK-US trade deal comes into effect today, leaving UK carmakers with reduced tariffs of 10 per cent and removing levies on the aerospace sector entirely. However, Britain's pharmaceutical sector still faces the potential for further tariffs down the line, as well as recent suggestions the White House could move to clamp-down on the price of medicines in the US. UK pharma sold £6.6billion worth of products to the US last year, meaning the sector is Britain's second-biggest export to the country. President Donald Trump's threat to end exemptions on pharma tariffs, which are driven by a 1995 World Trade Organisation deal, has sparked fears that disruption to the sector's highly complex supply chain could have implications for UK pharmacies and patients. Hikma said on Monday it has provided access 'to a wide range of generic medicines at a lower cost than branded products' since operating in the US since 1991. The group's 'America Leans on Hikma' strategy plans to increase the volume of 'essential medicines' developed and produced across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and New Jersey. Hikma said: 'This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients.' President of Hikma's generics business Dr. Hafrun Fridriksdottir added: 'We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients. 'Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.'
